Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy

Brian Tomlinson, Paul Chan, Yuzhen Zhang, Christopher Wai Kei Lam

研究成果: 雜誌貢獻回顧型文獻同行評審

摘要

Introduction: Statins are the first-line treatment to reduce cardiovascular (CV) events, mainly by reducing low-density-lipoprotein cholesterol (LDL-C), but many patients need additional treatments to reach the current lipid goals. Areas covered: Herein, the authors review the published literature on the efficacy and safety of the therapies that are most often added to statins to achieve lipid targets. Expert opinion: Ezetimibe is usually the first additional treatment to achieve LDL-C targets. It reduces LDL-C by about a further 20% and has an excellent safety and tolerability profile. The monoclonal antibody proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab, and alirocumab, can reduce LDL-C by ≥50% when added to statins and they also have a well-established safety and tolerability record. The recently approved bempedoic acid is well tolerated and appears to be free of skeletal muscle-related problems, but the CV outcome study with this drug has not been completed. Inclisiran, a small-interfering RNA targeting PCSK9 is at an advanced stage of development and the available data indicate a satisfactory safety profile and LDL-C lowering efficacy similar to the PCSK9 monoclonal antibodies with the advantage of less frequent administration.

原文英語
頁(從 - 到)2137-2151
頁數15
期刊Expert Opinion on Pharmacotherapy
21
發行號17
DOIs
出版狀態接受/付印 - 2020

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

指紋 深入研究「Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy」主題。共同形成了獨特的指紋。

引用此